Nov 18, 2024
Omnichannel transformation: Where’s the pharma industry at?
Every year we survey colleagues and customers from the life sciences industry to collate their perspectives on the state of digital transformation in their own organisation. From industry satisfaction to digital marketing budgets, Cx, AI, and more, the resulting Maturometer™ report aims to summarise pharma’s progress towards omnichannel maturity—as viewed by the people who work in it. Simply tap the button below and complete a short form in order to access this unique insight into the state of digital maturity in life sciences in 2024!
Please note: The Maturometer™ survey was issued by Across Health earlier this year; we have since rebranded to Precision AQ.
Get unmissable insights on a range of topics, including:
- Pharma digital budgets and internal satisfaction
- Most common bottlenecks for digital
- Global-to-local (in)efficiency
- Adoption of AI in customer engagement efforts
- Digital knowledge/skill levels
To give you an idea of what this year’s Maturometer™ offers, we are pleased to provide you with two highlights below.
Want to dive into the full report immediately?
In addition, you can watch the highlights of Maturometer™ 2024 being discussed by our experts in our recent webinar, with all slides available for download here.
MLR ISSUES AND ROI CONCERNS TOP THE LIST OF COMMON BOTTLENECKS FOR DIGITAL
Looking at the factors thought to be getting in the way of digital progress among EU biopharma organisations, MLR (Medical, Legal & Regulatory) issues and uncertainties around ROI continue to be an important obstruction for digital success—and the gap between these has closed significantly since last year’s survey. Meanwhile, lack of internal knowledge, technologies and strategy consistently fill out the top 5 bottlenecks, presenting opportunities for pharma to make use of better strategic planning, tracking and upskilling.
Are current investments failing to show results…or is there a lack of confidence/knowledge regarding the appropriate metrics for digital initiatives?
THERE IS SIGNIFICANT INTEREST IN AI, BUT ITS EFFECTIVE IMPLEMENTATION REMAINS CHALLENGING
When asked ‘What's the current level of adoption of Al in your company's customer engagement efforts?’, only 11% of European biopharma respondents reported no interest at all in AI in their organization. In fact, the data indicate a strong inclination to incorporate AI in customer engagement efforts, with over a third having progressed beyond the 'interested' stage to pilots and beyond.
Are they finding it challenging to turn their AI ambitions into reality because the basics—particularly data quality and organisation - are not yet in place?